2012-10-06 19:19:39 - Recently published research from Global Markets Direct, "Immupharma Plc - Product Pipeline Review - 2012", is now available at Fast Market Research

Global Market Direct's pharmaceuticals report, "Immupharma Plc - Product Pipeline Review - 2012" provides data on the Immupharma Plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Immupharma Plc's corporate website, SEC filings, investor presentations and featured press releases, both from Immupharma Plc and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468542_immupharma_plc_product_pipeline_revie ..


Scope

* Immupharma Plc - Brief Immupharma Plc overview including business description, key information and facts, and its locations and subsidiaries.

* Review of current pipeline of Immupharma Plc human therapeutic division.
* Overview of pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Immupharma Plc with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Immupharma Plc's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.

Reasons to buy

* Evaluate Immupharma Plc's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Immupharma Plc in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Immupharma Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Immupharma Plc.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Immupharma Plc and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Immupharma Plc Snapshot
Immupharma Plc Overview
Key Information
Key Facts
Immupharma Plc - Research and Development Overview
Key Therapeutic Areas
Immupharma Plc - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Immupharma Plc - Pipeline Products Glance
Immupharma Plc - Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Immupharma Plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Immupharma Plc - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Immupharma Plc - Drug Profiles
forigerimod
Product Description
Mechanism of Action
R&D Progress
IPP-102199
Product Description
Mechanism of Action
R&D Progress
IPP-201007
Product Description
Mechanism of Action
R&D Progress
IPP-203101
Product Description
Mechanism of Action
R&D Progress
IPP-204106
Product Description
Mechanism of Action
R&D Progress
Immupharma Plc - Pipeline Products by Route of Administration
Immupharma Plc - Pipeline Products By Mechanism of Action
Immupharma Plc - Recent Pipeline Updates
Immupharma Plc - Company Statement
Immupharma Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Immupharma Plc, Recent Developments
Immupharma Plc- Press Release
Nov 19, 2009: ImmuPharma Reports Positive Phase IIb Trial Results Of Lupuzor In Systemic Lupus Erythematosus
Feb 02, 2009: Cephalon Exercises Option To License Worldwide Rights To ImmuPharma Product, Lupuzor
Jan 30, 2009: ImmuPharma Announces Phase IIb Results Of Lupuzor To Placebo In Patients With Systemic Lupus Erythematosus
Financial Deals Landscape
Immupharma Plc, Deals Summary
Immupharma Plc, Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
Cephalon Enters Into Licensing Agreement With ImmuPharma For Lupuzor
ImmuPharma Enters Into Licensing Agreement With CNRS
Equity Offering
ImmuPharma Completes Private Placement Of $4.3 Million
ImmuPharma Completes Private Placement Of $2 Million
ImmuPharma Completes Private Placement Of $3 Million
ImmuPharma Completes Private Placement Of $5 Million
Debt Offering
ImmuPharma Completes Private Placement Of Unsecured Bonds For $3.94 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Immupharma Plc, Key Information
Immupharma Plc, Key Facts
Immupharma Plc - Pipeline by Indication, 2012
Immupharma Plc - Pipeline by Stage of Development, 2012
Immupharma Plc - Monotherapy Products in Pipeline, 2012
Immupharma Plc - Phase III, 2012
Immupharma Plc - Phase II, 2012
Immupharma Plc - Pre-Clinical, 2012
Immupharma Plc - Pipeline By Route of Administration, 2012
Immupharma Plc - Pipeline Products By Mechanism of Action, 2012
Immupharma Plc - Recent Pipeline Updates, 2012
Immupharma Plc, Subsidiaries
Immupharma Plc, Deals Summary
Cephalon Enters Into Licensing Agreement With ImmuPharma For Lupuzor

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468542&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.